Literature DB >> 23026932

Combined BRAF(V600E)-positive melanocytic lesions with large epithelioid cells lacking BAP1 expression and conventional nevomelanocytes.

Klaus J Busam1, Joanne Sung, Thomas Wiesner, Andreas von Deimling, Achim Jungbluth.   

Abstract

Recently a group of spitzoid melanocytic proliferations with loss of BAP1 expression has been reported. The lesions may occur sporadically or as part of a familial cancer syndrome. They have distinct histopathologic features characterized by a nevus-like silhouette and cytologic composition of large epithelioid melanocytes with oval vesicular nuclei, distinct nucleoli, and abundant cytoplasm with well-defined cytoplasmic borders. A characteristic immunohistochemical finding is loss of nuclear labeling for BAP1. In contrast to classic Spitz nevi, the lesions carry the BRAF mutation. They may present as a pure large epithelioid cell proliferation or as a combined lesion in association with a conventional nevus. Here we report a series of 8 combined melanocytic lesions, in which a dominant large epithelioid cell proliferation with loss of BAP1 expression was associated and intimately admixed with a BAP1-positive conventional nevus. These biphenotypic lesions were from 6 patients, 3 female and 3 male, ranging in age from 16 to 59 years. Immunohistochemical analysis for BAP1 showed loss of nuclear labeling confined to the large epithelioid melanocyte subpopulation. The conventional melanocytes retained BAP1 expression. Both large epithelioid and conventional melanocytes were immunoreactive with the monoclonal antibody VE1, which recognizes the protein encoded by mutant BRAF. In 6 cases the conventional nevus component was a compound nevus of small "type B" melanocytes. In 2 cases, the nevus remnant was entirely intradermal. The lesions described herein may represent a peculiar combined melanocytic nevus variant. However, longer follow-up and more studies are needed to determine the biological potential of the BAP1-negative melanocyte proliferations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23026932     DOI: 10.1097/PAS.0b013e318263648c

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

1.  Melanoma With Loss of BAP1 Expression in Patients With No Family History of BAP1-Associated Cancer Susceptibility Syndrome: A Case Series.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Michael T Tetzlaff; Jonathan L Curry; Guilin Tang; Zied Abdullaev; Svetlana D Pack; Doina Ivan; Victor G Prieto; Carlos A Torres-Cabala
Journal:  Am J Dermatopathol       Date:  2019-03       Impact factor: 1.533

2.  Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions.

Authors:  Klaus J Busam; Heinz Kutzner; Lorenzo Cerroni; Thomas Wiesner
Journal:  Am J Surg Pathol       Date:  2014-07       Impact factor: 6.394

3.  [Wiesner nevus: a new melanocytic tumor defined by molecular genetic analysis].

Authors:  C Hafner
Journal:  Hautarzt       Date:  2014-07       Impact factor: 0.751

4.  NRAS-mutated melanocytic BAP1-associated intradermal tumor (MBAIT): a case report.

Authors:  Willeke A M Blokx; Katrin Rabold; H Jorn Bovenschen; Marjolijn J L Ligtenberg; Arjen R Mensenkamp; Gesina van Lijnschoten; Wendy A G van Zelst-Stams; Patricia J T A Groenen
Journal:  Virchows Arch       Date:  2014-10-24       Impact factor: 4.064

Review 5.  Comprehensive review of BAP1 tumor predisposition syndrome with report of two new cases.

Authors:  K Rai; R Pilarski; C M Cebulla; M H Abdel-Rahman
Journal:  Clin Genet       Date:  2015-07-14       Impact factor: 4.438

6.  Multiple Cutaneous Melanomas and Clinically Atypical Moles in a Patient With a Novel Germline BAP1 Mutation.

Authors:  Pedram Gerami; Oriol Yélamos; Christina Y Lee; Roxana Obregon; Pedram Yazdan; Lauren M Sholl; Gerta E Guitart; Ching-Ni Njauw; Hensin Tsao
Journal:  JAMA Dermatol       Date:  2015-11       Impact factor: 10.282

7.  PBRM1 and BAP1 as novel targets for renal cell carcinoma.

Authors:  James Brugarolas
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

Review 8.  Genomic aberrations in spitzoid melanocytic tumours and their implications for diagnosis, prognosis and therapy.

Authors:  Thomas Wiesner; Heinz Kutzner; Lorenzo Cerroni; Martin C Mihm; Klaus J Busam; Rajmohan Murali
Journal:  Pathology       Date:  2016-01-18       Impact factor: 5.306

Review 9.  Biologically distinct subsets of nevi.

Authors:  Tova Rogers; Maria L Marino; Patricia Raciti; Manu Jain; Klaus J Busam; Michael A Marchetti; Ashfaq A Marghoob
Journal:  G Ital Dermatol Venereol       Date:  2016-04-27       Impact factor: 2.011

10.  Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society.

Authors:  Oriol Yélamos; Cristián Navarrete-Dechent; Michael A Marchetti; Tova Rogers; Zoe Apalla; Philippe Bahadoran; Nuria Blázquez-Sánchez; Klaus Busam; Cristina Carrera; Stephen W Dusza; Arnaud de la Fouchardière; Gerardo Ferrara; Pedram Gerami; Harald Kittler; Aimilios Lallas; Josep Malvehy; José F Millán-Cayetano; Kelly C Nelson; Victor Li Quan; Susana Puig; Howard Stevens; Luc Thomas; Ashfaq A Marghoob
Journal:  J Am Acad Dermatol       Date:  2018-09-20       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.